{"id":"acetazolamide-supplemental-oxygen-pap-therapy","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Paresthesias (tingling in extremities)"},{"rate":"10-30%","effect":"Altered taste (dysgeusia)"},{"rate":"30-50%","effect":"Increased urination (polyuria)"},{"rate":"common","effect":"Mild metabolic acidosis"},{"rate":"variable","effect":"Hypokalemia"},{"rate":"low","effect":"Oxygen-related complications (if prolonged)"}]},"_chembl":{"chemblId":"CHEMBL1234886","moleculeType":"Small molecule","molecularWeight":"32.00"},"_fixedAt":"2026-03-30T14:20:16.095211","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acetazolamide is a carbonic anhydrase inhibitor that causes metabolic acidosis, which stimulates ventilation and reduces periodic breathing patterns common at altitude. Supplemental oxygen directly increases arterial oxygen saturation. Positive airway pressure (PAP) therapy maintains airway patency and improves alveolar recruitment, collectively reducing hypoxemia and pulmonary edema formation.","oneSentence":"This combination therapy reduces periodic breathing and improves oxygenation in high-altitude pulmonary edema (HAPE) and related conditions by suppressing respiratory alkalosis, providing supplemental oxygen, and applying positive airway pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:26:26.857Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"High-altitude pulmonary edema (HAPE)"},{"name":"High-altitude cerebral edema (HACE) with respiratory compromise"},{"name":"Periodic breathing at altitude"}]},"_fixedFields":["pubmed(2)"],"trialDetails":[{"nctId":"NCT04118387","phase":"PHASE4","title":"Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-01-07","conditions":"Sleep Disordered Breathing, Able Bodied","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"recentPublications":[{"date":"2025 Jun","pmid":"40672884","title":"Altitude-Associated Central Apnea in Continuous Positive Airway Pressure Therapy.","journal":"Sleep science (Sao Paulo, Brazil)"},{"date":"2012 Jan 1","pmid":"22215916","title":"The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses.","journal":"Sleep"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Acetazolamide + supplemental oxygen + PAP therapy","genericName":"Acetazolamide + supplemental oxygen + PAP therapy","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy reduces periodic breathing and improves oxygenation in high-altitude pulmonary edema (HAPE) and related conditions by suppressing respiratory alkalosis, providing supplemental oxygen, and applying positive airway pressure. Used for High-altitude pulmonary edema (HAPE), High-altitude cerebral edema (HACE) with respiratory compromise, Periodic breathing at altitude.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}